✨ Free AI Report
Immune-Onc Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Immune-Onc Therapeutics, Inc.
Company Research

Immune-Onc Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Immune-Onc Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Early-stage myeloid checkpoint inhibitor developer with strong science backing and strategic partnerships, but execution and clinical trial success remain critical inflection points. Immune-Onc demonstrates solid fundamentals with $138M raised from established investors and a differentiated pipeline addressing an underexploited myeloid checkpoint target space. However, as a 13-person Series B.

What is Immune-Onc Therapeutics, Inc.'s industry? Immune-Onc Therapeutics, Inc. (immune-onc.com) operates in Oncology Drugs. AskCyborg classifies Immune-Onc Therapeutics, Inc. under Oncology Drugs in its company registry.

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patie...

6/ 10Solid

Cyborg Score thesis

Early-stage myeloid checkpoint inhibitor developer with strong science backing and strategic partnerships, but execution and...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Immune-Onc Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Immune-Onc Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Immune-Onc Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Immune-Onc Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Immune-Onc Therapeutics, Inc. Overview

Pro stress-test →

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patients. Founded in 2016 and headquartered in Palo Alto, the company focuses on first-in-class myeloid checkpoint inhibitors with a differentiated approach to cancer immunotherapy.

Strategic Profile

Pro stress-test →

The company has a focused pipeline targeting Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB) myeloid checkpoints, with lead programs IO-108 and IO-202 advancing through clinical trials. Immune-Onc has secured strategic partnerships with leading biopharmaceutical companies including BeiGene and Regeneron, and maintains research collaborations with top-tier institutions including Memorial Sloan Kettering Cancer Center.

Competitive Landscape

Pro stress-test →

Immune-Onc competes in the immuno-oncology space alongside companies developing checkpoint inhibitors and cellular immunotherapies. Direct competitors include Jazz Pharmaceuticals, Sana Biotechnology, and Kite Pharma. However, the company's specific focus on LILRB myeloid checkpoints differentiates it from the broader PD-1/PD-L1 checkpoint inhibitor market dominated by larger pharmaceutical companies.

Industry Context

Immune-Onc Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2016 · Headquarters: Palo Alto, US · Employees: 13

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Immune-Onc Therapeutics, Inc..

  • Lead candidate IO-108 began a global Phase 1b/2 trial (January 2026) in solid tumors, advancing from completed Phase 1 monotherapy data
  • Focused pipeline targeting underexploited LILRB myeloid checkpoints, a validated but less crowded segment than PD-1/PD-L1 checkpoint space
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026IO-108 advanced to Phase 1b/2 global trial in advanced solid tumors and combination studies with anti-PD-1 agents
  • January 2023Completed $131M Series B extension financing to advance IO-108 and IO-202 development
Get alerted when Immune-Onc Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Arcus BiosciencesImmuno-oncology company developing checkpoint inhibitors and antibodies→Jounce TherapeuticsImmuno-oncology company targeting checkpoint molecules and myeloid modulation→Cstone PharmaceuticalsClinical-stage biotech developing myeloid checkpoint inhibitors in immuno-oncology→Tmunity TherapeuticsImmuno-oncology company developing checkpoint inhibitor therapeutics→

Compare Immune-Onc Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Immune-Onc Therapeutics, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Immune-Onc Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Immune-Onc Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Immune-Onc Therapeutics, Inc. do this quarter?”
“Is Immune-Onc Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Immune-Onc Therapeutics, Inc. do?+
Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patie...
What is Immune-Onc Therapeutics, Inc.'s Cyborg Score?+
Immune-Onc Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Immune-Onc Therapeutics, Inc.'s main competitors?+
Named competitors include Arcus Biosciences, Jounce Therapeutics, Cstone Pharmaceuticals, Tmunity Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Immune-Onc Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Immune-Onc Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Immune-Onc Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.